Long-term outcome of patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency

American Journal of the Medical Sciences

Volumn 344, Issue 5, 2012, Pages 363-373

  Mnif, Mouna Feki ^a   Kamoun, Mahdi ^a   Mnif, Fatma ^a   Charfi, Nadia ^a   Kallel, Nozha ^a   Naceur, Basma Ben ^a   Rekik, Nabila ^a   Mnif, Zainab ^a   Sfar, Mohamed Habib ^b   Sfar, Mohamed Tahar ^b   Hachicha, Mongia ^a   Keskes, Leila Ammar ^c   Abid, Mohamed ^a  

^a HEDI CHAKER HOSPITAL   (Tunisia)

^b Tahar Sfar University Hospital   (Tunisia)

^c Faculty of Medicine   (Tunisia)

Author keywords

Bone mineral density; Cardiometabolic risk; Congenital adrenal hyperplasia; Fertility; Final height; Quality of life

Indexed keywords

INHIBIN B; MUELLERIAN INHIBITING FACTOR; STEROID 21 MONOOXYGENASE;

ADOLESCENT; ADULT; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD PRESSURE MONITORING; BODY HEIGHT; BONE; BONE DEMINERALIZATION; CARDIOMETABOLIC RISK; CLINICAL ARTICLE; COGNITION; CONGENITAL ADRENAL HYPERPLASIA; DISORDERS OF CARBOHYDRATE METABOLISM; FEMALE; FERTILITY; HUMAN; INSULIN RESISTANCE; MALE; NEUROIMAGING; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; OVARY POLYCYSTIC DISEASE; PATIENT COMPLIANCE; QUALITY OF LIFE; SEMEN ANALYSIS; STEROID 21 MONOOXYGENASE DEFICIENCY; TREATMENT OUTCOME;

EID: 84867675097     PISSN: 00029629     EISSN: 15382990     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e31824369e4     Document Type: Article

References (54)

1. White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Endocr Rev 2000;21:245-91.
2. Forest MG, Tardy V, Nicolino M, et al. 21-Hydroxylase deficiency: an exemplary model of the contribution of molecular biology in the understanding and management of the disease. Ann Endocrinol 2005;66:225-32.
3. Ogilvie CM, Crouch NS, Rumsby G, et al. Congenital adrenal hyperplasia in adults: a review of medical, surgical and psychological issues. Clin Endocrinol 2006;64:2-11.
4. Merke DP, Chrousos GP, Eisenhofer G, et al. Adrenomedullary dysplasia and hypofunction in patients with classic 21-hydroxylase deficiency. N Engl J Med 2000;343:1362-8.
5. Ambroziak U, Bednarczuk T, Ginalska-Malinowska M, et al. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency - management in adults. Endokrynol Pol 2010;61:142-55.
6. Eugster EA, Dimeglio LA, Wright JC, et al. Height outcome in congenital adrenal hyperplasia caused by 21-hydroxylase deficiency: a meta-analysis. J Pediatr 2001;138:26-32.
7. Guo CY, Weetman AP, Eastell R. Bone turnover and bone mineral density in patients with congenital adrenal hyperplasia. Clin Endocrinol 1996;45:535-41.
8. Falhammar H, Filipsson H, Holmdahl G, et al. Fractures and bone mineral density in adult women with 21-hydroxylase deficiency. J Clin Endocrinol Metab 2007;92:4643-9.
9. Arisaka O, Hoshi M, Kanazawa S, et al. Preliminary report: effect of adrenal androgen and estrogen on bone maturation and bone mineral density. Metabolism 2001;50:377-9.
10. Mooij CF, Kroese JM, Claahsen-van der Grinten HL, et al. Unfavourable trends in cardiovascular and metabolic risk in paediatric and adult patients with congenital adrenal hyperplasia? Clin Endocrinol 2010;73:137-46.
11. Kim MS, Merke DP. Cardiovascular disease risk in adult women with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Semin Reprod Med 2009;27:316-21.
12. Gastaud F, Bouvattier C, Duranteau L, et al. Impaired sexual and reproductive outcomes in women with classical forms of congenital adrenal hyperplasia. J Clin Endocrinol Metab 2007;92:1391-6.
13. Johannsen TH, Ripa CP, Reinisch JM, et al. Impaired cognitive function in women with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2006;91:1376-81.
14. Bergamaschi R, Livieri C, Uggetti C, et al. Brain white matter impairment in congenital adrenal hyperplasia. Arch Neurol 2006;63:413-6.
15. Arlt W, Willis DS, Wild SH, et al. Health status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients. J Clin Endocrinol Metab 2010;95:5110-21.
16. Nermoen I, Husebye ES, Svartberg J, et al. Subjective health status in men and women with congenital adrenal hyperplasia: a populationbased survey in Norway. Eur J Endocrinol 2010;163:453-9.
17. Jääskeläinen Voutilainen R. Long-term outcome of classical 21- hydroxylase deficiency: diagnosis, complications and quality of life. Acta Paediatr 2000;89:183-7.
18. Joint LWPES/ESPE CAH Working Group. Consensus statement on 21-hydroxylase deficiency from the Lawson Wilkins Pediatric Endocrine Society and the European Society for Paediatric Endocrinology. J Clin Endocrinol Metab 2002;87:4048-53.
19. Hatch R, Rosenfield RL, Kim MH, et al. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol 1981;140:815-30.
20. Prader A, Gurtner HP. Das Syndrom des Pseudohermaphrotismus masculinus bei kongenitaler Nebennierenindenhyperplasie ohne androgenub-erproduktion (adrenaler Pseudohermaphroditismus masculinus). Helv Paediatr Acta 1955;10:397-412.
21. Muirhead S, Sellers EA, Guyda H; Canadian Pediatric Endocrine Group. Indicators of adult height outcome in classical 21-hydroxylase deficiency congenital adrenal hyperplasia. J Pediatr 2002;141:247-52.
22. Bates DW, Black DM, Cummings SR. Clinical use of bone densitometry: clinical applications. JAMA 2002;288:1898-900.
23. Gabir MM, Hanson RL, Dabelea D, et al. The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. Diabetes Care 2000;23:1108-12.
24. Matthews DR, Hosker JP, Rudenski AS, et al. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28:412-9.
25. Radikova Z, Koska J, Huckova M, et al. Insulin sensitivity indices: a proposal of cut-off points for simple identification of insulin-resistant subjects. Exp Clin Endocrinol Diabetes 2006;114:249-56.
26. Stone NJ, Bilek S, Rosenbaum S. Recent National Cholesterol Education Program Adult Treatment Panel III update: adjustments and options. Am J Cardiol 2005;96:53E-59E.
27. Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 2007;25:1105-87.
28. Liivak K, Tillmann V. 24-hour blood pressure profiles in children with congenital adrenal hyperplasia on two different hydrocortisone treatment regimens. J Pediatr Endocrinol Metab 2009;22:511-7.
29. Stein JH, Korcarz CE, Hurst RT, et al. Use of carotid ultrasound to identify subclinical vascular disease and evaluate cardiovascular disease risk: a consensus statement from the American Society of Echocardiography Carotid Intima-Media Thickness Task Force. Endorsed by the Society for Vascular Medicine. J Am Soc Echocardiogr 2008;21:93-111.
30. Denarié N, Gariepy J, Chironi G, et al. Distribution of ultrasonographically- assessed dimensions of common carotid arteries in healthy adults of both sexes. Atherosclerosis 2000;148:297-302.
31. Kliesch S, Cooper TG. [Semen analysis: spermiogram according to WHO criteria]. Urologe A 2008;47:1550-4.
32. Trivax B, Azziz R. Diagnosis of polycystic ovary syndrome. Clin Obstet Gynecol 2007;50:168-77.
33. Gandek B, Ware JE Jr. Methods for validating and norming translations of health status questionnaires: the IQOLA Project approach. International Quality of Life Assessment. J Clin Epidemiol 1998;51:953-9.
34. Coons SJ, Alabdulmohsin SA, Draugalis JR, et al. Reliability of an Arabic version of the RAND-36 Health Survey and its equivalence to the US-English version. Med Care 1998;36:428-32.
35. Atkinson L. Mental retardation and WAIS-R difference scores. J Ment Defic Res 1991;35:537-42.
36. Nguyen AT, Brown JJ, Warne GL. Growth in congenital adrenal hyperplasia. Indian J Pediatr 2006;73:89-93.
37. Speiser PW, Azziz R, Baskin LS, et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010;95:4133-60.
38. Hoepffner W, Kaufhold A, Willgerodt H, et al. Patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency can achieve their target height: the Leipzig experience. Horm Res 2008; 70:42-50.
39. Chakhtoura Z, Bachelot A, Samara-Boustani D, et al. Impact of total cumulative glucocorticoid dose on bone mineral density in patients with 21-hydroxylase deficiency. Eur J Endocrinol 2008;158:879-87.
40. Bachelot A, Chakthoura Z, Rouxel A, et al. Classical forms of congenital adrenal hyperplasia due to 21-hydroxylase deficiency in adults. Horm Res 2008;69:203-11.
41. Ivaska KK, Gerdhem P, Väänänen HK, et al. Bone turnover markers and prediction of fracture: a prospective follow-up study of 1040 elderly woman for a mean of 9 years. J Bone Miner Res 2010;25: 393-403.
42. Loechner KJ, Patel S, Fordham L, et al. Decreased bone mineral density and vertebral compression fractures in a young adult male with 21-hydroxylase deficiency congenital adrenal hyperplasia (CAH): is CAH an unrecognized population at risk for glucocorticoid-induced osteoporosis? J Pediatr Endocrinol Metab. 2010;23:179-87.
43. Charmandari E, Chrousos GP. Metabolic syndrome manifestations in classic congenital adrenal hyperplasia: do they predispose to atherosclerotic cardiovascular disease and secondary polycystic ovary syndrome? Ann N Y Acad Sci 2006;1083:37-53.
44. Völkl TM, Simm D, Dötsch J, et al. Altered 24-hour blood pressure profiles in children and adolescents with classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 2006;91:4888-95.
45. Sartorato P, Zulian E, Benedini S, et al. Cardiovascular risk factors and ultrasound evaluation of intima-media thickness at common carotids, carotid bulbs, and femoral and abdominal aorta arteries in patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab 2007;92:1015-8.
46. Reisch N, Flade L, Scherr M, et al. High prevalence of reduced fecundity in men with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2009;94:1665-70.
47. Claahsen-van der Grinten HL, Otten BJ, Stikkelbroeck MM, et al. Testicular adrenal rest tumours in congenital adrenal hyperplasia. Best Pract Res Clin Endocrinol Metab 2009;23:209-20.
48. Casteràs A, De Silva P, Rumsby G, et al. Reassessing fecundity in women with classical congenital adrenal hyperplasia (CAH): normal pregnancy rate but reduced fertility rate. Clin Endocrinol 2009;70:833-7.
49. Fanchin R, Schonäuer LM, Righini C, et al. Serum anti-Mullerian hormone is more strongly related to ovarian follicular status than serum inhibin B, estradiol, FSH and LH on day 3. Hum Reprod 2003;18:323-7.
50. Nass R, Heier L, Moshang T, et al. Magnetic resonance imaging in the congenital adrenal hyperplasia population: increased frequency of white-matter abnormalities and temporal lobe atrophy. J Child Neurol 1997;12:181-6.
51. Ernst M, Maheu FS, Schroth E, et al. Amygdala function in adolescents with congenital adrenal hyperplasia: a model for the study of early steroid abnormalities. Neuropsychologia 2007;45:2104-13.
52. Sapolsky RM. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry 2000;57:925-35.
53. Nordenskjöld A, Holmdahl G, Frisén L, et al. Type of mutation and surgical procedure affect long-term quality of life for women with congenital adrenal hyperplasia. J Clin Endocrinol Metab 2008;93:380-6.
54. Johannsen TH, Ripa CP, Mortensen EL, et al. Quality of life in 70 women with disorders of sex development. Eur J Endocrinol 2006;155: 877-85.